Why is the Nanosonics (ASX:NAN) share price crashing 16%?

Nanosonics is having a tough day…

| More on:
A woman holds her hands to the side of her face as she sits back in shock at something she is reading or seeing on her computer screen.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • Nanosonics' North American sales agreement with GE Healthcare is ending
  • The company is building up its direct sales team and taking things in house
  • Second half sales to be impacted and costs to increase

The Nanosonics Ltd (ASX: NAN) share price is under pressure on Tuesday morning.

In early trade, the infection prevention company's shares are down 16% to a 52-week low of $4.21.

Why is the Nanosonics share price sinking today?

Investors have been selling down the Nanosonics share price today after it revealed big changes in the North American market.

According to the release, the current GE Healthcare sales model will be revised from 8 February 2022 until the expiry of the current agreement in June 2022. The release does not make clear which party is driving the change.

Under the revised North American sales model, GE Healthcare will consume inventory and transition to a passthrough sales model for its ongoing sales of trophon to be made exclusively through its ultrasound sales team.

What is the new model?

The new model will see Nanosonics manage all inventory, ship, install and train the new GE trophon customers, which will become Nanosonics' customers for the ongoing provision of consumables.

In addition, GE will commence the transition of all existing GE trophon customers to Nanosonics for the ongoing provision of all consumables. During this transition, both companies will have a focus on ensuring a positive customer experience with no disruption in continuity of customer supply.

Positively, the company highlights that it has a well-established logistics operation based in Indianapolis. And with the planned expansion of these resources, it believes it will be well positioned to manage the transition and ensure the ongoing continuity of supply to customers.

Nanosonics' Chief Executive Officer & President, Michael Kavanagh, commented: "The revision to the North American sales model represents another significant milestone in the ongoing growth of the organisation and is consistent with our evolution to an increasingly direct sales model and OEM capital reseller channel strategy over time."

"Discussions are underway with GE Healthcare to commence a new capital reseller agreement at the expiry of the current agreement in June 2022 and we look forward to the opportunity to continue the successful relationship that we have had with GE over the last 10 years," he added.

What financial impact will this have?

The transition is expected to have an overall one-off impact on revenue in FY 2022 in the range of $13 million to $16 million.

This reflects a proportion of the anticipated growth in the second half being deferred to FY 2023 as the transition to the new sales model is implemented.

In addition, the company is going to have to increase its direct sales operations by the end of the fourth quarter of FY 2022. These operations will be tasked with continuing market growth momentum, where management believes a significant opportunity remains for the trophon franchise across new installed base, upgrades and consumables.

The increase in operating expenses associated with the expansion of the North American teams is expected to be approximately $1 million in the second half.

In the meantime, Nanosonics revealed that it expects to report first half sales of $60.6 million later this month. This will be a 41% increase over the prior corresponding period.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns and has recommended Nanosonics Limited. The Motley Fool Australia owns and has recommended Nanosonics Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

A young woman holds an open book over her head with a round mouthed expression as if to say oops as she looks at her computer screen in a home office setting with a plant on the desk and shelves of books in the background.
Healthcare Shares

This ASX All Ords share is diving 18% as inflation pain draws blood

This healthcare company delivered a trading update at its annual general meeting today.

Read more »

Shot of a young scientist using a digital tablet while working in a lab.
Healthcare Shares

Up 427% this year, why today is a big day for Mesoblast shares

Why is everyone talking about Mesoblast shares on Friday?

Read more »

A man holds his hand under his chin as he concentrates on his laptop screen and reads about the ANZ share price
Healthcare Shares

Is this beaten-down ASX healthcare share a bargain buy now?

One expert has given their view on this stock.

Read more »

drug capsule opening up to reveal dollar signs signifying rising asx share price
Healthcare Shares

3 ASX healthcare shares going gangbusters on Thursday

Investors are sending these ASX healthcare stocks soaring today. But why?

Read more »

Two lab workers fist pump each other.
Healthcare Shares

Is it time to cash in on Sigma shares?

Shares have extended after the Chemist Warehouse merger.

Read more »

Person holding Australian dollar notes, symbolising dividends.
Healthcare Shares

Buy this ASX 200 share that is swimming in cash

Bell Potter sees potentially big returns on offer from this cashed-up stock.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Are CSL shares a buy after the biotech's FY25 forecasts?

Brokers continue to weigh in.

Read more »

Female pharmacist smiles with a digital tablet.
Healthcare Shares

Are Wesfarmers or Sigma shares a better buy in the pharmacy arena?

These two stocks are both leaders in the industry.

Read more »